Sangamo BioSciences, Inc. (Nasdaq:SGMO)
HIV infection results in the death of immune system cells, particularly CD4+ T-cells leading to AIDS, a condition in which the body’s immune system is depleted to such a degree that the patient is unable to fight off common infections. Ultimately, these patients succumb to opportunistic infections or cancers.
SGMO reported the presentation of clinical data from its program to develop a ZFP Therapeutic(R) for HIV/AIDS. The data were presented at a translational medicine meeting organized by The Lancet and Cell publications and entitled, "What Will it Take to Achieve an AIDS-Free World?" which is being held in San Francisco, November 3-5, 2013.
SGMO 's goal is to develop an immunologic approach to HIV that should enable the patient's immune system to attack HIV infection at the level of both the HIV DNA viral reservoir and circulating viral load, and, according to the company, its data on immunologic analyses suggest that they are seeing these effects in SB-728-T treated subjects and the SB-728-T treatment protects long-term central memory CD4 T-cells from HIV-infection.
SGMO 's SB-728-T is a ZFN-based approach for modification of the gene encoding CCR5, the major co-receptor used by HIV to infect cells of the immune system.
ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV.
SGMO is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. SGMO has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic(R) for the treatment of HIV/AIDS.
More about Sangamo BioSciences, Inc. (Nasdaq:SGMO) at www.sangamo.com .
**
Crown Equity Holdings Inc. (CRWE)
Looking to deliver value for its stockholders in both the near and long term, CRWE is refocusing its strategic plan for future growth and services with its original online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise, targeting the multi-billion dollar B2B Industry with its iB2B Global project.
iB2B Global will give buyers, sellers, manufacturers and dealers the best exposure to the international market by providing a business platform to exhibit their products and introduce their companies
Strategic plans are also being developed for CRWE ’s online video-sharing project to improve the potential future growth for the company.
Online video is proving to be a powerful marketing tool for many businesses. Video has moved from a ‘nice to have’ to a ‘must have’. Indeed, if a business is not doing video, they are now behind the competition, according to Sage Lewis, a leading Digital Marketing expert in a recent seminar.
CRWE is targeting this multi-billion dollar market with its Division CRWETube ( www.crwetube.com )
Together with its digital network of websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher. CRWE focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
***
Read Full Disclaimer at www.pennyomega.com/disclaimer
